Intranasal esketamine use in bipolar disorder: A case report
Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
American Association of Psychiatric Pharmacists,
2021-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|